Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Flexion Therapeutics Inc. FLXN

Healthcare Drug Manufacturers - Major
Flexion Therapeutics Inc is a United States-based specialty pharmaceutical company. The company focuses on the development and commercialization of novel, local therapies. The company specializes in the treatment of patients with musculoskeletal conditions beginning with osteoarthritis. The products offered by company are zilretta which is used for enhancing the clinical effect of intra... see more

Recent & Breaking News (NDAQ:FLXN)

Flexion Therapeutics Announces Publication of Results from Pivotal Phase 3 Study of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in the Journal of Bone and Joint Surgery

GlobeNewswire April 18, 2018

12 Stocks Moving In Tuesday's After-Hours Session

Benzinga.com  October 10, 2017

Flexion Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire October 10, 2017

Flexion Therapeutics to Hold Conference Call at 8:00 a.m. ET to Discuss Recent FDA Approval of ZILRETTA™ (triamcinolone acetonide extended-release injectable suspension)

PR Newswire October 9, 2017

Flexion Therapeutics Announces FDA Approval of Zilretta™ (triamcinolone acetonide extended-release injectable suspension) for Osteoarthritis (OA) Knee Pain

GlobeNewswire October 6, 2017

Flexion Therapeutics to Present Data on Zilretta™ (FX006) at PAINWeek 2017

GlobeNewswire September 7, 2017

Technical Snapshots for These Generic Drugs Stocks -- Catalyst Pharma, Flexion Therapeutics, Supernus Pharma, and Lannett

PR Newswire September 5, 2017

Flexion Therapeutics to Present at the 2017 Wells Fargo Healthcare Conference

GlobeNewswire August 30, 2017

Flexion Therapeutics Reports Second Quarter 2017 Financial Results and Recent Business Highlights

GlobeNewswire August 8, 2017

Investor Network: Flexion Therapeutics, Inc. to Host Earnings Call

Accesswire August 8, 2017

Flexion Therapeutics to Report Second-Quarter 2017 Financial Results on August 8, 2017

GlobeNewswire August 1, 2017

How These Generic Drugs Stocks are Performing? -- Akari Therapeutics, Flexion Therapeutics, Lannett, and Supernus Pharma

PR Newswire July 31, 2017

Flexion Therapeutics to Hold Investor & Analyst Day Today

GlobeNewswire July 10, 2017

Flexion Therapeutics to Hold Investor and Analyst Day on July 10, 2017

GlobeNewswire July 3, 2017

Flexion Therapeutics Announces Appointment of Mark Levine as General Counsel

GlobeNewswire June 28, 2017

Flexion Therapeutics Named One of Boston Business Journal’s Best Places to Work

GlobeNewswire June 23, 2017

Flexion Therapeutics to Present Data on Zilretta™ (FX006) at the American Diabetes Association’s 77th Scientific Sessions

GlobeNewswire June 10, 2017

Flexion to Present New Cost-Effectiveness Data on Zilretta™ (FX006) at the International Society for Pharmacoeconomics and Outcomes Research 22nd International Meeting

GlobeNewswire May 22, 2017

How These Generic Drugs Stocks are Faring? -- MYOS RENS Technology, Akari Therapeutics, Flexion Therapeutics, and Zynerba Pharma

PR Newswire May 19, 2017

Flexion Therapeutics Announces Upcoming Data Presentation at the American Diabetes Association's 77th Scientific Sessions

GlobeNewswire May 18, 2017